Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Medullary × Ranitidine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2 Breast Neoplasms 2 Renal Insufficiency 1 Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Paraproteinemias 1 Neoplasms, Plasma Cell 1 Neoplasms by Histologic Type 1 Multiple Myeloma 1 Leukemia 1 Kidney Neoplasms 1 Hematologic Diseases 1 Carcinoma, Renal Cell 1 Carcinoma, Medullary 1 Breast Carcinoma In Situ 1 Brain Neoplasms 1 Blood Protein Disorders 1 Advanced Cancer 1

Interventions

vandetanib 14 cabozantinib 8 selpercatinib 6 Everolimus 5 Sorafenib 4 Magnetic Resonance Spectroscopy 3 Capecitabine 3 sargramostim 2 pralsetinib 2 lutetium Lu 177 dotatate 2 lenvatinib 2 Trastuzumab 2 Temozolomide 2 Sunitinib 2 Octreotide 2 Gefitinib 2 yeast-CEA vaccine 1 veliparib 1 vatalanib 1 tumor necrosis factor-alpha, CNGRC fusion protein, human 1 tipifarnib 1 temsirolimus 1 tanespimycin 1 sacubitril and valsartan sodium hydrate drug combination 1 ponatinib 1 pentetreotide 1 pembrolizumab 1 pazopanib 1 pasireotide 1 nintedanib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01539655 2017-05-02

Vandetanib

Sanofi

Phase 1 Completed

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡